However, there is sparse data on the possible impact of novel antidiabetic therapeutics, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), on the risk for CRC development and recurrence. This evidence concerns the gene GLP1R and colorectal carcinoma.